Cresset Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Cresset Asset Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-26,000	Closed	-$30K	–	750
2022 Q3	$30K	Hold	26,000	–	–	﹤0.01%	869
2022 Q2	$17K	Hold	26,000	–	–	﹤0.01%	929
2022 Q1	$68K	Hold	26,000	–	–	﹤0.01%	963
2021 Q4	$101K	Buy	26,000 +1,000	+4%	+$5.02K	﹤0.01%	1079
2021 Q3	$109K	Hold	25,000	–	–	﹤0.01%	1065
2021 Q2	$99K	Buy	+25,000	New	+$99.8K	﹤0.01%	996

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAFP

Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cresset Asset Management's AQST Position: Q4 2022 in Review

Cresset Asset Management sold out of Aquestive Therapeutics (AQST) in Q4 2022, closing a stake of 26,000 shares — an estimated $30K sold.

Cresset Asset Management first reported a position in AQST in Q2 2021 and held it in 6 quarters. The position peaked at $109K in Q3 2021. 37 funds tracked by Wall St. Rank hold AQST as of Q4 2022.

Cresset Asset Management reported no remaining Aquestive Therapeutics position as of Q4 2022 after selling out during the quarter.
Cresset Asset Management sold 26,000 Aquestive Therapeutics shares in Q4 2022, an estimated $30K.
Cresset Asset Management first reported a position in Aquestive Therapeutics in Q2 2021 and held it in 6 quarters.
Cresset Asset Management's Aquestive Therapeutics position peaked at $109K in Q3 2021.
37 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2022.

Based on Cresset Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.